Summary:
A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy snd safety of 4 oral does of BI 425809 once daily over a 12 week period in patients with Schizophrenia
Qualified Participants Must:
Men or Woman age 18-50
Must have Schizophrenia
Qualified Participants May Receive:
Compensation for time and travel